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Abbreviations
CABG coronary artery bypass grafting
CI confidence interval
DAPT dual antiplatelet therapy
ESC European Society of Cardiology
HR hazard ratio
Hs-TnT high-sensitivity troponin T
MI  myocardial infarction
NNH number needed to harm
NSTE ACS non-ST elevation acute coronary syndromes
PCI percutaneous coronary intervention
RRR relative risk reduction
STEMI ST elevation myocardial infarction
The contemporary paradigm for managing high-risk NSTE ACS 
involves an invasive strategy with the use of antithrombotic therapy 
to reduce ischaemic complications and recurrent adverse cardio-
vascular events while simultaneously avoiding bleeding complica-
tions. Pre-treatment (before coronary angiography) with P2Y12 
inhibitors and aspirin has been shown to be of no advantage in low-
risk patients; conversely, CLARITY-TIMI 28 and TRITON-TIMI 
38 suggested a benefit for pre-treatment in very high-risk patients 
(acute STEMI)1,2. Pre-loading in NSTE ACS with clopidogrel has 
been based on the positive results of the randomised CURE study3, 
which included medically managed patients who did not undergo 
systematic catheterisation and an observational subset (PCI-CURE) 
who did receive PCI (21% of the cohort at 10 days). This intro-
duction along with the objectives of the session was enunciated 
by Thomas Cuisset and served as the context for the Comparison 
of Prasugrel at PCI or Time of Diagnosis of Non-ST Elevation 
Myocardial Infarction (ACCOAST) trial4 and the subsequent dis-
cussion at EuroPCR.
The invited panellists ranged from those with active experience 
of clinical cardiology from around Europe (Andreas Baumbach 
[UK], Marco Valgimigli [The Netherlands], Rod Stables [UK], 
Franz-Josef Neumann [Germany], Stefan James [Sweden]) to 
a cardiovascular epidemiologist (Peter  Jüni [Switzerland]) and the 
principal investigator of ACCOAST himself (Gilles Montalescot 
[France]).
Franz-Josef Neumann framed the discussion with a real-life case 
history from his hospital. Rod Stables delivered an evidence-based 
overview of antithrombotic therapy of ACS past and present. He 
*Corresponding author: Département de Cardiologie, CHU La Timone, France 
E-mail: Thomas.CUISSET@ap-hm.fr
409
Will this trial change my practice? ACCOAST
EuroIntervention 2
0
1
4
;10
:408-410
ended with four questions for the audience and practitioners to pon-
der. “(1) Do such studies reflect the totality of the patients? (2) Do 
such studies capture all adverse events? (3) Are there significant 
angio-PCI time delays in the studies? (4) Is there an evidence-based 
choice for ACS patients who do not receive PCI?”
Indeed, the chair questioned the relevance of ACCOAST to his 
general interventional practice, as he frequently received patients 
over the weekend or on call overnight, who could not undergo 
immediate or even urgent PCI for medical reasons or due to the 
logistics of the weekend.
Montalescot re-acquainted the audience with the data (Figure 1), 
presented in 2013, of this large (n=4,038) international (>50% 
recruited from Europe) multicentre, randomised study. In 
a NSTEMI population the investigators set out to evaluate the supe-
riority of systematic upstream (“pre-loading”) DAPT (aspirin and 
prasugrel) using a split loading dose of prasugrel 30 mg followed 
by a further 30 mg in the cathlab if PCI was to be performed versus 
upstream placebo followed by 60 mg in the cathlab if PCI was per-
formed. Invasive coronary angiography with or without ad hoc PCI 
was mandated between 2 and 48 hours post-randomisation. One 
panellist asked whether this was “really a study looking at prasu-
grel or early invasive therapy”. The trialist admitted it was the lat-
ter also, but benefit of pre-treatment was assessed in the study as 
well. Peter  Jüni posed a question on the efficacy of study alloca-
tion concealment which was not described in the original publica-
tion. Furthermore, he commented that “the trial had an 80% power 
to detect a 24% RRR with 400 primary endpoint events. The trial 
was “terminated prematurely but 398 events had occurred by that 
time making it still adequately powered”. The primary composite 
endpoint of reduced cardiovascular death, myocardial infarction, 
stroke, urgent revascularisation, or glycoprotein IIb/IIIa inhibitor 
bail-out through seven days from randomisation was not met (10% 
vs. 9.8%) by prasugrel and, importantly, there were more major 
bleeds (access, non-access as well as non-CABG-related) than in 
the reference arm (2.6% and 1.4%, respectively, for TIMI major; 
HR 1.9, 95% CI: 1.19-3.02, p=0.0006, NNH 84), causing the 
p
p
Figure 1. Summary slide taken from PCR trials book.
monitoring board to terminate the study prematurely. In pre-speci-
fied higher risk subgroups, including patients treated with PCI, sim-
ilar results were found.
Does this mean that all pre-loading with P2Y12, as supported 
by current ESC guidelines (1C recommendation for “as soon as 
possible”), is unnecessary and harmful? Peter  Jüni praised the 
refreshing trial design “which was different to studies typically 
orientated to academic institutions” and felt that “the increasingly 
rapid access to acute cardiology services, pre-hospital assessment 
and initial treatment by paramedic staff, and the need for CABG 
in a proportion of patients make this a relevant question for prac-
tising cardiologists worldwide”. This view was supported by del-
egates in the audience.
The cohort studied was representative of a broad NSTEMI pop-
ulation and included 25% at high risk as calculated by a GRACE 
score >140 points. All were troponin-positive and 54% had ischae-
mic ECG changes. The bleeding risk was moderate in the group as 
a whole (median CRUSADE score 33). The median time to inva-
sive coronary angiogram was an impressive 4.3 hours. Although 
Gilles Montalescot countered the criticism from the audience that 
this did not reflect real-world practice by pointing out these trans-
fer times were “similar to other contemporary NSTE ACS studies 
such as TIMACS and OASIS 7”, Baumbach and Stables nevertheless 
insisted that “external validity was limited as for many units there are 
delays due to transfer logistics to a PCI-capable unit, apparent clini-
cal stability and comorbidity”. These delays without DAPT may risk 
ischaemic injury that has been seen previously with a “cooling off” 
strategy5. Stables wondered if the endpoint criteria had included tro-
ponin assessment. Montalescot confirmed that they had. The appar-
ent “lack of difference most likely reflects early access to invasive 
assessment and treatment” said Baumbach. “The excess early bleed-
ing hazard, however, underlined the importance of ischaemic and 
bleeding risk profiles”. A member of the audience commented that 
systematic transfer of “troponin-positive” patients who are not true 
NSTEMI (type 2 MI) exposes them to pre-treatment bleeding risk of 
potent antithrombotic therapy without benefit and so may have con-
tributed to the outcomes recorded. In the ACCOAST trial a medical 
strategy was pursued in 25.1% of the patients.
All panellists commented that the results could not be extrapolated 
to the other potent P2Y12, ticagrelor. Indeed, the main question was 
to discuss if ACCOAST showed no benefit of pre-treatment with 
strong P2Y12 blockers including ticagrelor (“strategy study”) and no 
benefit of pre-treatment with prasugrel specifically (“drug study”).
How can this study apply to daily practice? A poll of the audi-
ence indicated clearly that, while the ACCOAST was interesting 
as it challenged the guidelines, it would not change practice for 
the majority of their units owing to an average 48-hour or more 
delay from diagnosis to invasive therapy. However, in centres with 
short delay (<48 hrs) to the cathlab for NSTEMI, panellists rec-
ognised the validity of the ACCOAST study. Bringing directly to 
the cathlab, however, as a NSTE ACS, then waiting to define the 
coronary anatomy before thienopyridine loading seemed more pru-
dent and was supported by the study results with the caveat that we 
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must wait for more data on ticagrelor pre-treatment. For those cases 
where the diagnosis is not clearly NSTE ACS then this study did 
support withholding additional antiplatelet therapy until the coro-
nary anatomy is defined. Rod Stables still made the case for more 
flexibility in whether to pre-treat or not, as he would be “more com-
fortable pre-treating a 40-year-old man with a low risk of bleed-
ing than an elderly woman with a small build”. Stefan James and 
Marco Valgimigli, wrapping up the session, pointed out that “rather 
than dogmatically applying a policy of systematic pre-treatment or 
not, a more appropriate conclusion may be that we need to indi-
vidualise antithrombotic therapy much more and focus on bringing 
appropriately triaged high-risk NSTE ACS to the cathlab sooner”. 
As a final thought, the chairman summed up the feelings of many in 
the audience by declaring that there remained “confusion following 
the data from ACCOAST but at a higher level”.
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